Semaglutide for Smoking Cessation in Patients With Diabetes

What this study is about

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

Who can join (things the study team will check)

✅ You may be able to join if…

• Adults (18 years or older) with type 2 diabetes
• Currently residing in Ontario
• Smoke at least five cigarettes per day and willing to reduce or quit smoking within the next 6 months
• Stable HbA1c ≥7.0% - 10% with no more than a 1% change over the last 3 to 6 months.
• Have not used GLP-1 receptor agonists in the past six months.
• Able to provide informed consent

🚫 You may not be able to join if…

• Pregnant or breastfeeding individuals
• Contraindication to NRT or GLP-1 RA.
• Current daily use of NRT or a GLP1 RA.
• Use of bupropion, cytisine, and varenicline within the last 7 days.
• Use of a DPP-IV inhibitor within the last 7 days.
• Initiation of a new diabetes medication within the last 3 months.
• As per the product monograph, participants with the following diagnoses or disorders will be excluded;
• Personal or family history of medullary thyroid cancer
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
• Diabetic ketoacidosis
• Type I diabetes
• Acute pancreatitis or pancreatic cancer
• Acute, chronic or end-stage renal failure
• Tachyarrhythmias
• Unable to engage in follow-up for any reason (for example an acute mental illness, cognitive impairment, unable to speak English or French).
• Other conditions deemed by the study team to interfere with participation or outcomes in the opinion of the study investigator (for example acutely unwell, life expectancy less than 1 year).

Where this trial is running

• University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Who to contact

Evyanne Quirouette · 613-696-7000 · equirouette@ottawaheart.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07059377.